News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:
   

TechnoVax Inc. Reports on a VLP Vaccine Designed to Protect Against the Devastating 1918 Pandemic Influenza As Well As a Novel Bivalent VLP Vaccine Candidate


7/18/2007 10:46:29 AM

TARRYTOWN, N.Y.--(BUSINESS WIRE)--TechnoVax Inc., a vaccine biotechnology company located in Tarrytown, NY presented results based on its novel virus-like particle (VLP) technology at the American Society for Virology Annual Meeting, being held at Oregon State University, Corvallis Oregon. Preclinical data on its 1918 VLP vaccine, designed to protect against the highly virulent 1918 pandemic influenza virus that killed approximately 50 million people worldwide, showed protection against a surrogate virus in animals. Also, TechnoVax, Inc. presented data on its novel bivalent VLP vaccine technology which creates VLP vaccines each bearing two antigenically distinct molecules. A single bivalent VLP will afford protecting against two antigenically distinct influenza viruses.

Read at BioSpace.com


comments powered by Disqus
   
Influenza
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES